<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03674658</url>
  </required_header>
  <id_info>
    <org_study_id>TSHRH1801-P</org_study_id>
    <nct_id>NCT03674658</nct_id>
  </id_info>
  <brief_title>Propafenone in the Treatment of Atrial Fibrillation</brief_title>
  <official_title>An Open-Label Randomized Study of Propafenone in the Treatment of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TSH Biopharm Corporation Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TSH Biopharm Corporation Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a open label randomized, multi-center study conducted in Taiwan. The study aims to&#xD;
      evaluate the effectiveness and safety of oral Rhynorm (A drug) and Rytmonorm (B drug) for the&#xD;
      conversion of paroxysmal AF and is designed to evaluate the improvement in sinus rhythm&#xD;
      restoration after the treatment with Rhynorm (A drug) and Rytmonorm (B drug) for 24 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a open label randomized, multi-center study conducted in Taiwan. The study aims to&#xD;
      evaluate the effectiveness and safety of oral Rhynorm (A drug) and Rytmonorm (B drug) for the&#xD;
      conversion of paroxysmal AF and is designed to evaluate the improvement in sinus rhythm&#xD;
      restoration after the treatment with Rhynorm (A drug) and Rytmonorm (B drug) for 24 weeks.&#xD;
&#xD;
      This study comprised of three phases: a screening phase, a washout run-in qualifying phase&#xD;
      lasting about 7 days, and a treatment phase of 24 weeks. A total of 60 evaluable subjects is&#xD;
      planned to be enrolled. With an estimation of 20% dropout rate, 72 patients will be enrolled&#xD;
      to reach 60 evaluable patients at the end of study. After screening for eligibility, the&#xD;
      eligible subjects will be randomly assigned to either of the two gruop. The two-group are&#xD;
      shown in the following table.&#xD;
&#xD;
      Group Treatment Drug Group A Rhynorm (A drug) Group B Rytmonorm (B drug) Patients with&#xD;
      arrhythmia will be screened for eligibility after providing informed consent. Patients&#xD;
      present with the symptoms of arrhythmia after withdrawn from other prohibited anti-AF agents&#xD;
      for at least 7 days and completed run-in period event recorded will be qualified for entering&#xD;
      this study and will be randomized to Rhynorm (A drug) treatment group or Rytmonorm (B drug)&#xD;
      reference drud group in a 1:1 ratio.&#xD;
&#xD;
      The clinical evaluation will be recorded during the study period. Before treating with&#xD;
      Rhynorm (A drug) and Rytmonorm (B drug), the physical examination and condition will be&#xD;
      tracked and recorded for at least 7 days as the historical data.&#xD;
&#xD;
      During the treatment period, the subjects still had a routine OPD visit. Record symptom event&#xD;
      and event recorder monitoring on OPD visit.&#xD;
&#xD;
      Safety assessments on all randomized subjects include adverse events, vital signs, and&#xD;
      laboratory tests (hematology and biochemistry). Any adverse events, symptom events and&#xD;
      concomitant medications/therapies will be recorded on the CRFs throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2019</start_date>
  <completion_date type="Actual">August 17, 2021</completion_date>
  <primary_completion_date type="Actual">August 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group A: Rhynorm (A drug) Group B: Rytmonorm (B drug)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients with recurrent AF</measure>
    <time_frame>24 weeks treatment</time_frame>
    <description>To compare the effect of Rhynorm (A drug) and Rytmonorm (B drug) over 24 weeks of treatment based on the proportion of patients with recurrent AF</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>A drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rhynorm(A drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rytmonorm (B drug)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propafenone</intervention_name>
    <description>oral, TID</description>
    <arm_group_label>A drug</arm_group_label>
    <arm_group_label>B drug</arm_group_label>
    <other_name>A drug: Rhynorm</other_name>
    <other_name>B drug: Rytmonorm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who are 20~80 years of age&#xD;
&#xD;
          2. Recurrent AF patients&#xD;
&#xD;
          3. Patients with paroxysmal atrial fibrillation&#xD;
&#xD;
          4. Patients diagnosed with one of the ECG monitoring within 12 months prior screening&#xD;
             visit:&#xD;
&#xD;
               1. 12-lead electrocardiogram&#xD;
&#xD;
               2. ECG used to make a 30 second one of recording&#xD;
&#xD;
               3. 24 hours ECG (Holter Monitor)&#xD;
&#xD;
               4. Long term ECG (Event Monitor)&#xD;
&#xD;
          5. Patient may be receiving stable dose of propafenone since at least 4 weeks prior&#xD;
             screening visit.&#xD;
&#xD;
          6. Agree to and are able to follow the study procedures&#xD;
&#xD;
          7. Understand the nature of the study, and have signed informed consent forms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Permanent or persistent AF&#xD;
&#xD;
          2. Any of the following heart disease:&#xD;
&#xD;
               1. New York Heart Association class III or IV angina pectoris or heart failure&#xD;
&#xD;
               2. previous electrocardiographic evidence of second- or third-degree&#xD;
                  atrioventricular block;&#xD;
&#xD;
               3. Sinus node disease, AV conduction disturbance or bundle branch block in the&#xD;
                  absence of an artificial pacemaker&#xD;
&#xD;
               4. Hemodynamic moderate valvular heart disease (stenosis and/or incompetent;&#xD;
                  regurgitation)&#xD;
&#xD;
               5. Brugada syndrome&#xD;
&#xD;
               6. Left ventricular EF&lt; 50%&#xD;
&#xD;
               7. Acute myocardial infarction or unstable angina within the previous 12 months&#xD;
&#xD;
               8. Cardiogenic shock (excluding arrhythrmia shock) within the previous 12 months&#xD;
&#xD;
               9. Acute pericarditis or myocarditis within the previous 6 months&#xD;
&#xD;
              10. Cardiac or thoracic surgery within the previous 6 months&#xD;
&#xD;
          3. Symptomatic Bradycardia (heart rate less than 50 beats per minute)&#xD;
&#xD;
          4. Hemodynamic instability, defined as hypotension (SBP &lt; 90 mm Hg)&#xD;
&#xD;
          5. Hyperthyroidism&#xD;
&#xD;
          6. Bronchospastic disorders or severe obstructive pulmonary disease&#xD;
&#xD;
          7. Correctable AF for other reasons&#xD;
&#xD;
          8. Marked electrolyte imbalance&#xD;
&#xD;
          9. Patients with clinically significant abnormalities in the following laboratory&#xD;
             parameters:&#xD;
&#xD;
               1. AST or ALT ≥ 3X upper limit of normal (ULN)&#xD;
&#xD;
               2. Total bilirubin ≥ 2X ULN&#xD;
&#xD;
               3. Creatinine ≥ 2.5 mg/dL&#xD;
&#xD;
               4. Hemoglobin &lt; 10 g/dL&#xD;
&#xD;
               5. Platelet &lt; 100,000/uL&#xD;
&#xD;
         10. Patients with known contraindication or history of allergy to Propafenone.&#xD;
&#xD;
         11. Female patients who are pregnant or lactating.&#xD;
&#xD;
         12. Female patients of child-bearing potentiality who do not agree to use an effective&#xD;
             method of contraception during the study&#xD;
&#xD;
         13. Patients currently participating in any drug related clinical trial within 30 days&#xD;
&#xD;
         14. Patients with propagating factor (e.g. Alcohol Abuse induced AF)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propafenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

